Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.
Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke EM, Fasching P, Strumberg D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A, Marmé F. Mavratzas A, et al. Among authors: windemuth kieselbach c. Breast. 2019 Jun;45:22-28. doi: 10.1016/j.breast.2019.02.002. Epub 2019 Feb 13. Breast. 2019. PMID: 30822621 Clinical Trial.
Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx.
Hauswald H, Jensen AD, Krauss J, Haselmann R, Lossner K, Hartmann S, Windemuth-Kieselbach C, Münter MW, Debus J. Hauswald H, et al. Clin Transl Radiat Oncol. 2018 Sep 21;13:64-73. doi: 10.1016/j.ctro.2018.09.005. eCollection 2018 Nov. Clin Transl Radiat Oncol. 2018. PMID: 30370340 Free PMC article.
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, Rösch A, Simon JC, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group. Zimmer L, et al. Among authors: windemuth kieselbach c. Lancet. 2020 May 16;395(10236):1558-1568. doi: 10.1016/S0140-6736(20)30417-7. Lancet. 2020. PMID: 32416781 Clinical Trial.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group. Livingstone E, et al. Among authors: windemuth kieselbach c. Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099927 Clinical Trial.
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer.
Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R. Hadji P, et al. Ann Oncol. 2013 Jun;24(6):1505-12. doi: 10.1093/annonc/mds653. Epub 2013 Feb 1. Ann Oncol. 2013. PMID: 23378537 Free article. Clinical Trial.
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance.
Jackisch C, Kreienberg R, Blettner M, Harbeck N, Lück HJ, Haidinger R, Schmitt DC, Schulte H, Windemuth-Kieselbach C, Zaun S, Hadji P. Jackisch C, et al. Among authors: windemuth kieselbach c. Breast Care (Basel). 2020 Jun;15(3):236-245. doi: 10.1159/000500771. Epub 2019 Sep 25. Breast Care (Basel). 2020. PMID: 32774217 Free PMC article.
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Harbeck N, Blettner M, Hadji P, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Haidinger R, Schmitt D, Schulte H, Nitz U, Kreienberg R. Harbeck N, et al. Breast Care (Basel). 2013 May;8(2):110-20. doi: 10.1159/000350777. Breast Care (Basel). 2013. PMID: 24419247 Free PMC article.
30 results